Meldungen aus Calgary, Alberta

04.10.2017 – 14:03

ARC Energy Research Institute

ARC Energy Research Institute Report: How to Invest in Crude Oil in a Carbon Constrained World

Calgary, Alberta (ots/PRNewswire) - Responding to the need for more vigilant action on mitigating carbon emissions, the ARC Energy Research Institute ('ARC') has released "Crude Oil Investing in a Carbon Constrained World: 2017 Update ...

29.08.2017 – 20:03

Resverlogix Corp.

Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial

Calgary, Alberta (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that key findings from the recently completed CANTOS trial, which demonstrate that targeting residual inflammatory risk resulted in a reduction in the incidence of Major Adverse Cardiovascular ...

25.07.2017 – 15:02

Resverlogix Corp.

Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial

Calgary, Alberta (ots/PRNewswire) - "BETonMACE Phase 3 Trial with apabetalone to expand to include the United States" Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the receipt of a positive Type C written response from the Division of Metabolism and Endocrinology Products of the ...

10.07.2017 – 13:01

Resverlogix Corp.

Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial

Calgary, Alberta (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that the first patient has been randomized in Taiwan in the Phase 3 BETonMACE clinical trial with lead drug apabetalone intended for high-risk patients with cardiovascular disease ("CVD") and type 2 ...

31.05.2017 – 13:01

Resverlogix Corp.

Resverlogix to Host Epigenetics Focused Symposium at The ERA-EDTA Congress in Madrid, Spain

Calgary, Alberta (ots/PRNewswire) - The symposium titled: "Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?" at the ERA-EDTA Congress highlights BET-inhibition and apabetalone in addressing the significant unmet medical need in chronic kidney disease and cardiovascular disease. Resverlogix Corp. ...

30.05.2017 – 13:01

Resverlogix Corp.

Resverlogix Receives Approval From Health Canada to Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone

Calgary, Alberta (ots/PRNewswire) - Apabetalone expands in to first orphan disease clinical trial in patients with Fabry disease Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that it has received approval from Health Canada, Therapeutic Products Directorate, to proceed with a clinical ...

23.05.2017 – 13:01

Resverlogix Corp.

Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success

Calgary, Alberta (ots/PRNewswire) - Nature Reviews Nephrology and Pfizer Inc. discuss BET bromodomain inhibition and apabetalone as viable drug candidates Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today highlighted two additional works involving its lead drug, apabetalone, one recently published ...

15.05.2017 – 16:30

Resverlogix Corp.

Resverlogix Receives Approval From the FDA Cardiovascular and Renal Division to Proceed With a Requested Apabetalone Clinical Trial

Calgary, Alberta (ots/PRNewswire) - Apabetalone expands to a second major clinical indication in kidney dialysis patients Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the acceptance, by the Cardiovascular and Renal Products Division of the U.S. Food and Drug Administration ...

23.01.2017 – 13:01

Resverlogix Corp.

Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments

Calgary, Alberta (ots/PRNewswire) - Several Key Proteins That Drive Kidney (Renal) Disease and Dialysis Risk are Downregulated After a Single Dose of Apabetalone Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced preliminary results from the New Zealand based Phase 1 trial with severe ...

29.08.2016 – 17:58

Resverlogix Corp.

Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy

Calgary, Alberta (ots/PRNewswire) - The presentations at the ESC Congress symposium highlighted apabetalone and the opportunity and need for a novel approach to the treatment of high risk cardiovascular disease and diabetes. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Sunday, ...

11.08.2016 – 13:01

Resverlogix Corp.

Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board for Phase 3 Study of Apabetalone (RVX-208)

Calgary, Alberta (ots/PRNewswire) - A data review by the independent Data Safety Monitoring Board resulted in a verbal recommendation for the BETonMACE trial to continue as planned without any modification. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that the independent Data and ...

21.07.2016 – 21:29

Resverlogix Corp.

Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs

Calgary, Alberta (ots/PRNewswire) - The commencement of this Phase 1 pharmacokinentic (PK) trial in patients with severe renal impairment is the first in a series of planned clinical trials designed with value creation in mind. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that dosing ...

25.05.2016 – 01:52

Resverlogix Corp.

Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)

Calgary, Alberta (ots/PRNewswire) - "Apabetalone, a selective bromodomain extra-terminal (BET) protein inhibitor that significantly decreases abundance and activity of complement proteins" Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that new data was presented at the ERA-EDTA Congress in ...

26.10.2015 – 12:01

Resverlogix Corp.

Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone

Calgary, Alberta (ots/PRNewswire) - Apabetalone will be evaluated in a Phase 3 clinical trial in high-risk coronary artery disease and type 2 diabetes mellitus patients Resverlogix Corp. (the "Corporation") today announced the commencement of a Phase 3 clinical trial called 'BETonMACE' with lead drug apabetalone (RVX-208) in high-risk patients with ...

30.07.2015 – 21:25

RS Technologies Inc.

RS and Mosdorfer Announce Distribution Agreement

Calgary, Alberta And Weiz, Austria (ots/PRNewswire) - RS Technologies Inc. ("RS") and Mosdorfer GmbH, Mosdorfer CCL Systems Ltd. and EA Elektroarmaturen (collectively "Mosdorfer") are pleased to announce a new distribution agreement whereby Mosdorfer will act as an authorized, exclusive distributor of RS's composite utility poles to utility customers in the United Kingdom, certain European countries ...

21.07.2015 – 15:13

Resverlogix Corp.

Resverlogix Closes $50 Million Private Placement With Hepalink and Eastern Capital

Calgary, Alberta (ots/PRNewswire) - - TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix") announced today that it has closed the previously-announced private placement with Shenzhen Hepalink Pharmaceutical Co., Ltd. ("Hepalink") and Eastern Capital Limited ("Eastern"). Under the terms of the transaction, Hepalink subscribed for 13,270,000 units, each ...

08.07.2015 – 13:01

Resverlogix Corp.

Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink

Calgary, Alberta (ots/PRNewswire) - TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix") announced today that it has closed a license agreement and formally entered into a definitive stock purchase agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. ("Hepalink"). The closing of the stock purchase ...

22.06.2015 – 13:31

Resverlogix Corp.

Resverlogix Officially Attains Phase 3 Status With a European Regulatory Authority

Calgary, Alberta (ots/PRNewswire) - TSX Exchange Symbol: RVX Resverlogix Corp. today announced that following recent meetings with various European regulatory bodies, the first confirmation for our Phase 3 clinical plan has officially been received. A further regulatory and protocol design update will be provided to the market post the approval of additional ...

01.06.2015 – 13:34

Resverlogix Corp.

Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)

Calgary, Alberta (ots/PRNewswire) - RVX-208, the first selective bromodomain extra-terminal (BET) protein inhibitor, significantly reduces alkaline phosphatase (ALP) levels in patients with high vascular risk Resverlogix Corp. (the "Company") today announced that new data on RVX-208 was presented at the ERA-EDTA ...

27.04.2015 – 13:01

Resverlogix Corp.

Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement

Calgary, Alberta (ots/PRNewswire) - The deal structure involves CAD$50 million in equity investments, and future China sales milestones and licensing royalties that could represent in excess of US$400 million Resverlogix Corp. ("Resverlogix" or the "Company") today announced that it has entered into a Framework ...

07.04.2015 – 13:31

Resverlogix Corp.

Resverlogix Receives Two Patents for RVX-208 in China

Calgary, Alberta (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announces that it has received two China patent approvals covering RVX-208. A composition of matter patent, China No. 2007 8 0052349.8 titled, "Compounds for the Prevention and Treatment of Cardiovascular Disease" was granted until February 2027. A manufacturing patent, China No. ZL 2009 8 0106586.7 titled, ...

24.09.2014 – 22:55

SMART Technologies Inc

SMART Technologies Files Patent Infringement Lawsuit Against CTOUCH in the Netherlands

Calgary, Alberta (ots/PRNewswire) - SMART Technologies ULC today announced the filing of a patent infringement complaint in the Netherlands before the District Court of The Hague against CTOUCH EUROPE B.V. for infringement of SMART's European Patents EP 1 739 528 and EP 1 420 335 by the CTOUCH Leddura, Leddura XT ...

23.07.2014 – 16:12

Resverlogix Corp.

RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly in Patients with Diabetes Mellitus

Calgary, Alberta (ots/PRNewswire) - In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose metabolism. Resverlogix Corp. announced today findings from the recent analysis of Major Adverse Cardiovascular Events (MACE) data in ...

11.06.2014 – 06:14

Hitachi ID Systems, Inc.

One of the World's Largest Energy Companies Selects Calgary-Based Hitachi ID Identity Management Suite for Global Deployment

Calgary, Alberta (ots/PRNewswire) - Calgary-based Hitachi ID Systems [http://www.hitachi-id.com ] is pleased to announce that it was selected to provide identity management solutions for a multi-billion dollar energy company based out of Texas. Hitachi ID participated in a rigorous year-long selection process and ...

29.04.2014 – 06:02

Hitachi ID Systems, Inc.

Hitachi ID Systems Receives Integration Certification from ServiceNow

Calgary, Alberta (ots/PRNewswire) - Hitachi ID today announced it has received certification of its integration with ServiceNow(R) Certification by ServiceNow signifies that Hitachi ID Identity and Access Management Suite has successfully completed a set of defined tests focused on integration interoperability, security and performance. The certification ...

17.04.2014 – 06:02

Hitachi ID Systems, Inc.

Hitachi ID Systems Recognized as Leader in Identity Provisioning by Europe-based Analyst Firm KuppingerCole

Calgary, Alberta (ots/PRNewswire) - Hitachi ID Systems is named a Leader vendor in the 2014 Identity Provisioning Leadership Compass report, published by EU-based analyst firm, KuppingerCole. "We are very happy to be recognized by KuppingerCole in this research," says Gideon Shoham, CEO of Hitachi ID Systems. "Our ...

17.04.2014 – 06:02

Hitachi ID Systems, Inc.

Hitachi ID Systems Recognized as Leader in Identity Provisioning by Europe-based Analyst Firm Kuppinger Cole

12Nächste